Evidence map›Paper›PMID 22296587›Full record

ArticleBioconjugate chemistry2012

Reagents for astatination of biomolecules. 6. An intact antibody conjugated with a maleimido-closo-decaborate(2-) reagent via sulfhydryl groups had considerably higher kidney concentrations than the same antibody conjugated with an isothiocyanato-closo-decaborate(2-) reagent via lysine amines.

D Scott Wilbur, Ming-Kuan Chyan, Hirohisa Nakamae, Yun Chen, Donald K Hamlin, Erlinda B Santos, Brian T Kornblit, Brenda M Sandmaier

Abstract read
In one paragraph

Article in Bioconjugate chemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 68 citations in OpenAlex.

  1. Review
  2. Review
  3. Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024
    Article
  4. Review
  5. Article
  6. Development of [Leukemia · 2022
    Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Fused 1,2-Diboraoxazoles Based onMolecules (Basel, Switzerland) · 2021
    Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Chemical science · 2019
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

D Scott WilburDepartment of Radiation Oncology, University of Washington, Seattle, Washington, USA. dswilbur@u.washington.edu
Ming-Kuan Chyan
Hirohisa Nakamae
Yun Chen
Donald K Hamlin
Erlinda B Santos
Brian T Kornblit
Brenda M Sandmaier
Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa · ZAUniversity of Washington · US

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Marian Esvelt · 1985 to 2026
$296.4M
Development of Reagents for Labeling with At-211R01CA113431 · NCI · UNIVERSITY OF WASHINGTON · PI WILBUR, DANIEL SCOTT · 2005 to 2014
$2.3M
Astatine-211 Conditioning for Nonmyeloablative Hematopoietic Stem Cell AllograftsR01CA118940 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI SANDMAIER, BRENDA MARIE · 2006 to 2010
$1.4M
NCI NIH HHS CA113431NCI NIH HHS CA118940NCI NIH HHS P30 CA015704NCI NIH HHS R01 CA113431NCI NIH HHS R01 CA118940
6 · The paper itself

Abstract

We are investigating the use of an (211)At-labeled anti-CD45 monoclonal antibody (mAb) as a replacement of total body irradiation in conditioning regimens designed to decrease the toxicity of hematopoietic cell transplantation (HCT). As part of that investigation, dose-escalation studies were conducted in dogs using (211)At-labeled anticanine CD45 mAb, CA12.10C12, conjugated with a maleimido-closo-decaborate(2-) derivative, 4. Unacceptable renal toxicity was noted in the dogs receiving doses in the 0.27-0.62 mCi/kg range. This result was not anticipated, as no toxicity had been noted in prior biodistribution and toxicity studies conducted in mice. Studies were conducted to understand the cause of the renal toxicity and to find a way to circumvent it. A dog biodistribution study was conducted with (123)I-labeled CA12.10C12 that had been conjugated with 4. The biodistribution data showed that 10-fold higher kidney concentrations were obtained with the maleimido-conjugate than had been obtained in a previous biodistribution study with (123)I-labeled CA12.10C12 conjugated with an amine-reactive phenylisothiocyanato-CHX-A″ derivative. The difference in kidney concentrations observed in dogs for the two conjugation approaches led to an investigation of the reagents. SE-HPLC analyses showed that the purity of the CA12.10C12 conjugated via reduced disulfides was lower than that obtained with amine-reactive conjugation reagents, and nonreducing SDS-PAGE analyses indicated protein fragments were present in the disulfide reduced conjugate. Although we had previously prepared closo-decaborate(2-) derivatives with amine-reactive functional groups (e.g., 6 and 8), a new, easily synthesized, amine-reactive (phenylisothiocyanate) derivative, 10, was prepared for use in the current studies. A biodistribution was conducted with coadministered (125)I- and (211)At-labeled CA12.10C10 conjugated with 10. In that study, lower kidney concentrations were obtained for both radionuclides than had been obtained in the earlier study of the same antibody conjugated with 4 after reduction of disulfide bonds.

Indexed as

AminesAnimalsAntibodies, MonoclonalAstatineBoronDogsImmunoconjugatesIndicators and ReagentsIsothiocyanatesKidneyLysineSulfhydryl CompoundsAminesAntibodies, MonoclonalAstatineBoronImmunoconjugatesIndicators and ReagentsIsothiocyanatesLysineSulfhydryl Compounds

Identifiers

PMID22296587
PMCPMC3310299
OpenAlexW2007681758

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.